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Research has shown substantial support for the thesis that
dietary intervention slows the progression of chronic renal
failure.'·3 Although renal function in earlier studies was based
on changes in serum creatinine (Sa). the protective effect of a
low-protein (LP) diet was confirmed by Ihle et al. 4 who used
Supplemented low-protein
diets - are they superior in
chronic renal failure?
Twenty-two patients with chronic renal failure were
randomly assigned to a conventional low-protein diet
containing 0,6 g protein/kg/day or a very-low-protein diet
containing 0,4 g protein/kg/day supplemented with
essential amino acids; they were followed up for 9 months.
There were no significant changes in body mass index,
arm muscle area,. percentage body fat, serum albumin and
transferrin levels in any of the groups; neither was there
any difference between the groups in, respect of these
parameters. Renal function, as measured by the reciprocal
of serum creatinine over time, stabilised in both groups
during intervention, with no significant difference between
the groups. There was however no correlation between
changes in renal function and changes in blood pressure,
or dietary intake of protein, phosphorus, cholesterol,
polyunsaturated and saturated fatty acids. There were also
no significant changes and no significant differences
between the groups in serum levels of parathyroid
hormone and alkaline phosphatase, urine cyclic adenosine
monophosphate, tubular reabsorption of phosphate, and
the theoretical renal threshold for phosphate.
The results of this study suggest that the supplemented
very-low-protein diet was not superior to the conventional
low-protein diet in terms of its effect on protein-energy
status, renal function and biochemical parameters of renal
osteodystrophy.
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both 1/S and 51Cr-EDTA clearance as measures of this effect.
It is not dear whether amino acid supplementation of a very-
low-protein (VLP) diet is superior to the conventional LP diet.
Di Landro et al. 5 reported that a VLP diet plus essential amino
acids (EAAs) or keto acids can delay the rate of progression
compared with the conventional LP diet, but this effect may
have been due to a lower phosphorus intake, rather than a
lower protein intake. Unfortunately phosphorus intake was
not reported, but serum phosphate levels were significantly
lower after treatment with the VLP diet. Barsotti et a/. 6 also
found a significant slowing in the decline of creatinine
clearance on a VLP diet supplemented with EAAs or keto
acids. The supplemented VLP diet was, however, compared
with a diet high in protein and phosphorus. Therefore, the
protective effect may have been the result of protein and/or
phosphorus restrictions, and not EAAs or keto acids per se.
In practice there is very little difference between the total
protein intake on the conventional LP diet and a VLP diet
supplemented with EAAs; the main difference is the amino
acid composition and the types of food included in the diet.
Given the high cost ofEAA supplements, the question arises
as to whether EAA supplementation of the VLP diet in fact
offers an advantage over the conventional LP diet. Kopple'
argues that EAA supplementation offers potential
advantages in the lowering of phosphate and potassium
levels and normalisation of altered plasma and muscle
amino acid profiles, but that the value of these changes
have not been proven.
This study investigated the effect of the conventional LP
diet and a VLP diet supplemented with EAAs in respect of
the progression of chronic renal failure, nutritional status,
and biochemical evidence of renal osteodystrophy over a
period of 9 months.
Table I. Patient characteristics at entry {mean (SO))
Subjects and methods
Patients
The study protocol was approved by the Ethical Advisory
Committee of the Faculty of Medicine, University of
Stellenbosch. All predialysis outpatients at Tygerberg
Hospital between 18 and 65 years of age were screened
according to the following criteria: a history of confirmed
chronic renal failure for at least 6 months; Se, level 150 - 700
IJmoVI; no evidence of diabetes mellitus, liver disease,
alcoholism, underlying malignancy or psychiatric disorders;
no prescription for corticosteroids, cyclophosphamide,
angiotensin-converting enzyme inhibitors, calcium entry
blockers or other bone toxic drugs. The 22 patients who
qualified and gave informed consent were enrolled in the
dietary training period of the study, .during which time they
maintained their usual diet. To ensure that all patients
received the same standard of counselling, they all
participated in the same educational programme as
developed and tested by Herselman et al. 8 Each patient ~as
supplied with food scales for the weighing of food, and was
visited at home to optimise education. FollOWing the training
period of 8 weeks, patients were matched for underlying
nephropathy, Se,' creatinine clearance, known duration of
disease, age, sex and dietary knoWledge, and were then
randomly assigned to either the LP diet or a VLP diet
supplemented with EAAs. The normal treatment regimen of
each patient was adhered to, and Jrequency of medical
check-ups was not altered. The LP and VLP groups were
similar at entry (Table I).
Age Duration of Ser Cer Slope of Uprot Dietary
Group Case Diagnosis Sex (yrs) CRF(mo.) (~mol/I) (mVmin/1,73m2) 1/Ser x10" (gld) knowledge (%)
VLP 1 IgA M 34 24 345 18 -4,43 00,9 81
(N= 11) 2 PCK F 46 300 433 14 2,66 00,2 100
3 IN M 59 120 186 50 -0,83 00,1 92
4 MCGN F 26 48 230 31 -13,28 01,1 100
5 MCGN F 38 96 345 17 -7,08 00,0 53
6 MGN M 58 84 168 38 0,00 01,6 81
7 ICGN M 33 12 230 24 -0,89 03,3 64
8 MCGN M 36 60 318 34 -26,55 22,4 97
9 IN M 51 60 327 28 -3,54 00,3 94
21 PGN F 25 36 186 -5,31 36
22 Unknown M 61 12 389 17 -1,77 03,6 89
7M 4F 42 77 287 27 -5,31 03,4 79
(13) (81) (91) (11) (7,97) (6,8) (21)
LP 10 GN M 21 24 230 52 15,93 01,5 89
(N = 11) 11 IN F 42 18 141 56 0,00 00,2 94
12 PCK F 28 216 663 09 -4,43 00,4 64
13 MGN M 23 12 522 09 -97,35 12,6 81
14 CN M 59 24 239 38 -12,39 00,4 86
15 CN F 45 60 415 13 -6,20 00,2 80
16 IN F 56 36 194 44 -0,89 03,0 97
17 MGN M 65 24 469 17 -42,48 02,9 92
18 IN F 50 192 212 33 -0,89 00,0 100
19 PCK F 52 72 177 25 -7,08 00,0 86
20 FSGN M 35 36 221 30 -22,13 04,0 17
5M 6F 43 65 317 30 -15,93 02,3 81
(15) (71) (171) (17) (31,00) (3,7) (25)
P value' 0,9738 0,5302 0,9476 0,4904 0,8599 0,7905
·Comparison of the groups at entry (Wilcoxon 2-sample test).
IgA =immunoglobin A nephropathy; GN =glomerulonephritis; IN =interstitial nephropathy; PCK =polycystic kidneys; MGN =membranecus GN; CN = cortical necrosis; un =urinary tract infection;
FSGN =focal segmental GN; MCGN =mesangiocapillary GN; ICGN =immune complex GN; PGN =proliferative GN.
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Diet and medication
The LP and VLP diets are described in Table 11. All patients
received daily supplementation in the form of the water-
soluble vitamins and glucose polymers. Calcium carbonate
was prescribed in order to attain the recommended calcium
intake. Aluminium hydroxide was used in only 3 patients
with severe hyperphosphataemia (1 patient on the VLP diet
and 2 patients on the LP diet). Dietary intake before and
during the study was assessed by an experienced renal
dietitian by means of a quantitative food frequency
questionnaire (OFFO), validated against urea nitrogen
appearance""e for protein intake.
Table 11. Description of the LP and VLP dietary regimens, with




Nutrient Group intake study study P-value
Energy' LP 150t (35) 133 (47) 125 (34) 0,4772
(kJ/kg/d) VLP 150t (35) 132 (51) 116 (34) 0,2664
Protein' LP 0,60 1,04 (0,41) 0,73 (0,25) 0,0244
(g/kg/d) (70% HBY)




Calcium' LP 500 - 750 930 (742) 808 (212) 0,6835
(mg/d) VLP 500 - 750 871 (366) 730 (96) 0,3066
(mg/kg/d) LP 14 (9) 13 (5)
VLP 11 (4) 9 (2)
Phosphorus LP < 800 1135 (510) 741 (208) 0,0330
(mg/d) VLP < 800 1218 (453) 696 (262) 0,0039
(mg/kg/d) LP 17 (7) 11 (4)
VLP 15 (5) 9 (3)
Total fat LP 89 (41) 62 (30) 0,0300~
(g/d) VLP 99 (45) 54 (19) 0,0039~
PUFA LP 15 (6) 13 (5) 0,1596
(g/d) VLP 25 (8) 15 (6) O,O059~
SFA LP 30 (17) 19 (9) 0,0378
(g/d) VLP 38 (14) 18 (5) 0,0058~
PUFNSFA LP 0,63 (0,27) 0,78 (0,17) 0,0905
Ratio VLP 0,69 (0,17) 0,86 (0,41) 0,3032
CHOL LP 303 (226) 136 (69) 0,0440
(mg/d) VLP 327 (133) 148 (76) 0,0022
• Total intake from diet and supplements,
t All patients except for the obese received energy supplements in the form of Caloreen,
supplied by Roussel Laboratories,
~ Corrected for Upro,: for evert gram Upro" 1,2 g dietary protein was added,
~ Significant lower intakes during intervention (Wilcoxon sign rank test),
§ Supplied by Kabi Vrtrum AB,
HBV =high biological value; PUFA =polyunsaturated fatty acids; SFA =saturated fatty acids;
CHOL =cholesterol.
Anthropometric findings
Body weight and arm mi.Jscle area were assessed at
3-monthly intervals by the same investigator according to
internationally standardised methods."
Biochemical parameters
Blood samples were obtained by venepuncture after a 12-
hour fast and the following parameters were analysed: So<
levels, total calcium, ionised calcium, phosphate,
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magnesium, alkaline phosphatase, C-terminal parathyroid
hormone and albumin. All these were measured with a
Technikon SMAC II Autoanalyzer, except for ionised calcium
which was measured with the Nova 2 Analyzer, and
parathyroid hormone by means of radio-immunoassay."
Serum levels of calcium were corrected for albumin.'3
Twenty-four-hour urine samples were collected every 3
months for assessment of proteinuria, which was
determined tUrbidimetrically,14 as well as creatinine
clearance, urinary urea, phosphate and creatinine levels, all
of which were measured with a Beckman Astra 8. Tubular
reabsorption of phosphate and the theoretical renal
threshold for phosphate were calculated from the data
according to the formulae of Agus,15 and Walton and
Bijvoet,'6 respectively. Urinary creatinine was expressed as a
function of body weight to assess completeness of 24-hour
urine samples. The urinary urea level was used to determine
dietary protein intake from urea nitrogen appearance" and to
serve as an independent check on the OFFO. Urinary
calcium levels were measured with the Technikon SMAC 11
Autoanalyzer and expressed in ~mol/1 00 ml glomerular
filtrate. Cyclic adenosine monophosphate levels were
determined from a hydrated random urine sample using
Amersham's RIA kit, and expressed in nmol/100 ml
glomerular filtrate.
Statistical analyses
Spearman's correlation coefficient was used on the
combined data of the two groups to examine the
correlations between variables. The Wilcoxon 2-sample test
was used for comparisons between groups, while the
Wilcoxon sign rank test and the Friedman test were used to
test for significant differences between baseline and
intervention data. Progression of chronic renal failure was
assessed from changes in creatinine clearance and by
plotting of 1/Ser against time. Retrospective results for Ser
and blood pressure were obtained from medical files for a
mean period of 21 months to assess changes in renal
function and blood pressure. The repeated median




Renal function, as measured by 1/Se" deteriorated
significantly in both groups before entry, and then stabilised
during the study (Table Ill). There was no difference between
the groups with regard to the rate of progression before
(P = 0,4904) or during (P = 1,0000) the study. Creatinine
clearance also remained stable during intervention (Table IV).
No correlations were found between changes in 1/So< against
time and changes in systolic/diastolic blood pressure
(r = -0,2033/-0,1022; P = 0,3767/0,6594), and changes in
dietary intake of protein (r = 0,0481; P = 0,8403), phosphorus
(r =0,3265; P =0,1486), cholesterol (r =-0,1714; P = 0,4575),
polyunsaturated fatty acids (r = 0,1743; P = 0,4623) and
saturated fatty acids (r = -0,1936; P = 0,4003).
-
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Table Ill. Changes in the slope of 1/Scr and mean blood pressure








groups (Table IV). The most marked abnormalities included
increased serum levels of parathyroid hormone and alkaline
phosphatase, increased urinary cyclic adenosine
monophosphate, and decreased tubular reabsorption of
phosphate and theoretical renal threshold for phosphate.
LP (N =11) -0,18 (0,35) -0,05 (0,10) 140/87 144/89
(17/9) (23/12)
P-value 0,0415' O,2131 t O,1878/0,2034t
VLP (N = 11) -0,06 (0,09) -0,01 (0,12) 149/92 150/96
(18/9) (14/8)
P-value 0,0191' 0,4755t O,4471/0,1699t
LP+VLP (N =22) -0,12 (0,26) -0,02 (0,11) 145/90 147/92
(18/9) (18/10)
P-value 0,0021' 0,1474t O,7779/0,1699t
• Significant deterioration before intervention.
t Stabilisation during intervention.
t No change in mean systolicldiastolic BP (Wilcoxon sign rank test).
Table IV. Changes in anthropometric and biochemical parameters
at baseline and following intervention (mean (SO))
LP diet VLP diet
Parameter Baseline 9 months Baseline' 9 months
Anthropometry
BMI (kglm') 24 (5) 24 (5) 25 (4) 25 (4)
AMA(cm~ 49 (14) 50 (14) 51 (12) 53 (13)
Body fat (%) 26 (11) 27 (12) 31 (7) 32 (7)
Blood
Salb (gll) 39 (9) 43 (5) 39 (9) 41 (5)
Srrans (gll) 3,3 (0,9) 3,3 (0,6) 3,0 (1,1) 3,2 (0,8)
ScPTl1 (pmol/l) 127 (150) 139 (143) 105 (46) 122 (75)
SALP (UII) 131 (85) 123 (90) 105 (36) 101 (31)
Sp(mmol/I) 1,4 (0,6) 1,2 (0,5) 1,3 (0,3) 1,3 (0,2)
SCa (mmol/I) 2,3 (0,1) 2,3 (0,2) 2,3 (0,2) 2,3 (0,2)
SCa++ (mmol/I) 1,2 (0,1) 1,2 (0,1) 1,2 (0,1) 1,2 (0,1)
Smg (mmolll) 0,8 (0,1) 0,8 (0,2) 0,8 (0,1) 0,8 (0,0)
Urine
Ccr (ml/min/1,73 m~ 30 (17) 32 (14) 27 (11) 28 (15)
Uprot (g/d) 2,3 (3,7) 0,7 (0,8) 3,4 (6,8) 2,2 (3,0)
Ucr (mmol/kg) 0,2 (0,1) 0,2 (0,0) 0,2 (0,0) 0,2 (0,1)
Uc-AMP (nmo1/100 ml GF) 5,9 (3,7) 5,4 (7,6) 4,5 (2,3) 5,5 (4,6)
UCa (~moIl1 00 ml GF) 8,6 (7,9) 5,8 (6,6) 3,5 (3,1) 3,9 (2,6)
TRP(%) 59 (18) 57 (12) 54 (16) 60 (13)
TmP/GFR 0,7 (0,2) 0,7 (0,2) 0,7 (0,2) 0,7 (0,2)
No significant changes.
BMI ::: Body mass index; AMA ::: ann muscle area; Salb ::: serum albumin; Srrans ;;: serum
transferrin; ScFTH ::: serum parathyroid hormone; SA!.P ::: serum alkaline phosphatase~ Sp ::: serum
phosphate; Sea::: serum total calcium; Sea..... ::: serum ionised calcium; Smg ::: serum magnesium;
CC(::: creatinine clearance; Uprot ::: urinary protein; Ucr ::: ~rinwy creatinine; Ut-AMp::: urinary
cyclic adenosine monophosphate; GF =glomerular filtrate; TAP =tubular reabsorption of
phosphate; TmP/GFR =theoretical renal threshold of phosphate.
Diet and anthropometric findings
There were significant reductions in the intakes of protein,
phosphorus an'd dietary fats during intervention in both
groups, but there were no differences between the groups in
respect of these nutrients (Table 11). There were also no
significant differences between the groups in respect of
serum protein levels and anthropometric readings (Table IV).
Changes in protein intake were inversely correlated with
changes in serum albumin levels (r = -G,49; P = 0,029), but
not proteinuria (r = 0,1522; P = 0,5219).
Biochemical parameters of renal
osteodystrophy
There were no significant changes in biochemical parameters
of renal osteodystrophy and no difference between the
~ Volume 85 No.5 May 1995 SAMJ
Discussion
In this study, on both diets the rates of deterioration of renal
function were apparently slowed, indicating that some factors
other than EAAs were primarily involved. Among the
mechanisms preViously suggested to explain a protective
effect of a LP diet on renal function is the concept of
hyperfiltration,18 as well as the effect of protein intake on urine
concentration" and the charge-seleg;tive properties of the
glomerular basement membrane.'o In addition to dietary
protein, both dietary phosphorus" and fats" have been;
incriminated in the progression of renal disease. However..the
lack of correlation between changes in renal function and
dietary intake of protein, phosphorus, cholesterol and dietary
fats in this study suggests that the stabilisation of 1/Scr may
have been a consequence of non-dietary factors. The change
in 1/Scr cannot be explained by a change in mean blood
pressure either. It is, however, possible that better control of
blood pressure may have played a role in individual patients.
Bergstrom et a/. 23 have shown that slowing of disease
progression was at least partly due to better control of blood
pressure - with a significant correliltion between changes in
mean blood pressure and the slope of creatinine clearance.
The findings of our study therefore question the beneficial role
of dietary treatment on renal function.
Protein and energy intakes were apparently sufficient to
maintain protein and energy reserves in both groups over a
period of 9 months. Vujic D'Djukanovic'4 also found that
nutritional status was well preserved in patients treated with
a LP diet and a VLP diet supplemented with EMs, with no
difference between the groups, and Guarnieri et al;25 and
Rosman et al. 25 reported that anthropometric values
remained stable after more than 4 years of treatment with LP
diets. Although the energy requirement for nitrogen balance
may be somewhat higher, the level of energy required for
prevention of weight loss on LP diets was found to be
approximately 122 kJ/kg/d.25•27 There was no significant
difference in the energy intake between the LP and VLP
groups in our study, but it was more difficult to reach the
energy recommendations on the VLP diet - with the result
that mean energy intake in this group was o'1ly 116 kJ/kg/d
compared with the 125 kJ/kg/El on the LP diet. In the long
term, VLP diets supplemented with EMs may therefore
suffer from energy deficiency, and have an adverse effect on
protein metabolism and nitrogen balance, unless a practical
method can be found to increase energy intake further. The
I")egative correlation between changes in dietary protein and
serum albumin levels found in this study supports the
observations of Kaysen et al. 28 that LP diets are associated
with a reduction in proteinuria and an increase in serum
albumin. No association could, however, be demonstrated
between changes in protein intake and urinary protein in our
stUdy. It is possible that urinary protein undergoes more
acute changes in response to protein intake than could be
detected by 3-monthly investigations of proteinuria and the
assessment of mean protein intake over 9 months.
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Renal osteodystrophy is a frequent complication of
chronic renal failure, usually comprising hypocalcaemic
secondary hyperparathyroidism and/or impaired skeletal
mineralisation.29 As in the case of nutritional status and renal
function, there was no change in biochemical parameters of
renal osteodystrophy and no difference between the groups
in this regard. Although VLP diets supplemented with EAAs
have the potential advantage of a lower intake of
phosphorus and hence a beneficial effect on renal bone
disease, in this study the intake was not significantly lower
than on the conventional LP diet.
In conclusion, this study faile9 to prove a VLP diet
supplemented with EAAs superior to the conventional LP
diet over a period of 9 months. Furthermore, although
nutritional status was preserved on both diets, a
contributory role of dietary intervention in the stabilisation of
renal function could not be confirmed. Interpretation of
results must, however, take due cognisance of the
limitations of the small sample size and the use of Ser and
creatinine clearance'" as sole markers of renal function.
This study was supported by grants from Kabi Vitrum AB,
Stockholm, Sweden; Adcock-Ingram Laboratories Ltd, South
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Expenditure on health
research in South Africa,
1991/1992
M. S. Blecher, D. Mclntyre
Objective. To determine expenditure on health research in
South Africa in 1991/1992.
Design. Data from the financial statements of large
statutory councils conducting research in South Africa, as
well as other relevant reports, particularly the Department
of National Education's (NATED) survey of research
institutions, were analysed.
Results. A total of R198,7 million was spent on health
research in 1991/1992, 56,1 % by the tertiary education
sector and 20,7% by the Medical Research Council. Only
1,1% of expenditure on health was spent on research.
Less than 9% of health research expenditure by tertiary
educational institutions is classified within the category of
'comprehensive medicine' (which includes community
health, epidemiology and nutrition); whereas 82% of
expenditure by autonomous government institutions is so
classified.
Conclusions. Given that expenditure on health research
in South Africa is relatively low by international standards,
an increase in expenditure by both the public and private
sectors should be considered. Given the scarcity of
research resources, there should be adequate planning,
co-ordination, and particularly prioritisation of resource
allocations, so that research can be directed towards
addressing the country's health needs.
S Atr Med J 1995; 85: 365-370.
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